DSP107 + atezolizumab

DSP107 + atezolizumab is a combination therapy consisting of DSP107, a first-in-class bispecific fusion protein that targets both CD47 and 4-1BB, and atezolizumab, a monoclonal antibody targeting PD-L1. DSP107 is engineered to bind CD47 overexpressed on tumor cells, blocking the "don't eat me" signal to phagocytes and simultaneously presenting a 4-1BB ligand that costimulates and activates T cells. This dual mechanism aims to trigger both innate (via macrophage and polymorphonuclear leukocyte activation) and adaptive (via T-cell activation and cytotoxicity) anti-tumor immune responses. Atezolizumab further unleashes T cell activity by blocking PD-L1-mediated immune evasion, providing a synergistic immunotherapeutic approach. This combination has been tested in clinical studies in microsatellite stable metastatic colorectal cancer and other solid tumors[1][2][3][4].

Other names

DSP107 + TecentriqDSP107 + anti-PD-L1DSP107 + atezolizumab